K-Beauty clinical trials have devolved into a profit-driven circus where testing labs unbundle basic device metrics to inflate fees, while subject recycling and data manipulation threaten scientific validity. Domestic brands overspend on superficial device scores, whereas fast-growing brands opt for cost-effective user surveys. Overseas, lax clinical data poses catastrophic legal risks under post-market compliance systems like MoCRA (US) and CPNP (Europe).

Beauty executives still chase isolated active ingredients, trapped in one-dimensional dots. True market velocity demands an evolutionary leap from raw technical skill to a unified three-dimensional business architecture. The vanity mirror mercilessly exiles hollow marketing hype; only an ecosystem aligned from lab to shelf secures the final re-order. Is your brand building an unassailable solid, or merely floating in a fragmented dot? The market already knows.